



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Ulesfia™ Lotion

Common Name: Benzoyl Alcohol

PDL Category: Topical- Scabies and Pediculicides

| <u>Comparable Products</u> | <u>Preferred Drug List Status</u> |
|-------------------------------|-----------------------------------|
| Lindane | Non-Preferred |
| Ovide® | Non-Preferred |
| Permethrin | Preferred |
| Pyrethrins-Piperonyl Butoxide | Preferred |

Summary

Indications and Usage: Topical treatment of head lice infestation in patients 6 months of age and older.¹

Mechanism of Action: Inhibits the lice from closing respiratory spiracles, thus resulting in asphyxiation.¹

Dosage Forms: Lotion: 5%

Recommended Dosage: Apply to dry hair, completely covering the scalp and hair. Rinse off with water after 10 minutes. Repeat in 7 days.¹

Common Adverse Drug Reactions: Ocular irritation, application site irritation, application site anesthesia and hypoesthesia.¹

Contraindications: None¹

Manufacturer: Contract Pharmaceuticals Limited.

Analysis: Ulesfia™ Lotion is a new topical treatment indicated to treat head lice infestation in patients 6 months of age and older. Ulesfia™ was moderately effective in eliminating lice in the 2 studies used to gain FDA approval. Treatment with Ulesfia™ must be repeated, as the drug has no ovicidal activity. Fourteen days after the second treatment, 76.2% and 75% of lice were eliminated. Resistance is unlikely to occur due to the mechanism of action. Preferred alternatives appear on the Preferred Drug List, which have similar clinical efficacy and are more cost effective. Therefore, it is recommended that Ulesfia™ be added to the Preferred Drug List as a non-preferred drug.

IME Recommendation:

| | |
|---|---|
| <input type="checkbox"/> Preferred Drug | <input type="checkbox"/> Recommended Drug |
| <input checked="" type="checkbox"/> Non-Preferred Drug | <input type="checkbox"/> Non-Recommended Drug |
| <input type="checkbox"/> Preferred Drug with Conditions | |

1. Ulesfia™ [package insert]. Atlanta, GA: Sciele Pharma, Inc.; 2009.